These results suggest that the activation of DPP-4 in the kidney has an important role in TGF-β signaling and the progression of renal disease and that targeted therapy that inhibits DPP-4 may prove to be a useful new approach in the management of progressive renal disease, including kidney fibrosis. This evidence concerns the gene DPP4 and kidney disorder.